Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Operating Leases (2024 - 2025)

Historic Operating Leases for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $6.0 million.

  • Xilio Therapeutics' Operating Leases fell 1794.02% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 1794.02%. This contributed to the annual value of $7.0 million for FY2024, which is N/A changed from last year.
  • Xilio Therapeutics' Operating Leases amounted to $6.0 million in Q3 2025, which was down 1794.02% from $6.3 million recorded in Q2 2025.
  • Over the past 5 years, Xilio Therapeutics' Operating Leases peaked at $7.9 million during Q1 2024, and registered a low of $6.0 million during Q3 2025.